R&D Systems

Executive Summary

R&D Systems is a privately held, global leader in life science research reagents, headquartered in Minneapolis. Founded in 1976, the company develops and distributes high-quality antibodies, proteins, ELISA kits, and small molecules through its core brand and subsidiaries Tocris and Novus Biologicals. Serving academic, government, and biopharmaceutical research institutions, R&D Systems holds an estimated valuation of ~$8.3 billion with 156 million shares outstanding. The company's extensive product portfolio and established reputation position it as a critical supplier in the life sciences ecosystem, though its private status limits public financial disclosures. Growth is likely driven by continued demand for research tools in drug discovery and diagnostics, with potential for strategic acquisitions to expand its product offering.

Upcoming Catalysts (preview)

• 2026Launch of next-generation multiplex assay platform for proteomics65% success
• 2026Acquisition of a complementary life science tools company to expand portfolio60% success
• 2027Expansion of manufacturing capacity for recombinant proteins and antibodies75% success